Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 24, 2024 -- For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death through an apoptosis-like process, is feasible and safe and can prevent the need for insulin therapy when combined with semaglutide, according to a study presented at UEG Week, the annual meeting of United European Gastroenterology, held from Oct. 4 to 7 in Vienna.
Celine Busch, M.D., from Amsterdam University Medical Center, and colleagues presented 24-month results from a single-arm, single-center, first-in-human study conducted in 14 patients with T2D. All patients underwent the ReCET procedure, followed by a two-week isocaloric liquid diet; semaglutide was titrated up to 1 mg/week thereafter.
The researchers found that the technical success rate of the ReCET procedure was 100 percent; the median axial treatment length was 12 cm, and median procedure time was 58 minutes. There were no serious adverse events related to the device or severe hypoglycemic events. Thirteen of the patients (93 percent) tolerated the maximum dose of semaglutide. Twelve patients (86 percent) were still not using insulin at six and 12 months, but they had significant improvements in glycemic control and metabolic parameters. All 11 patients who completed the 24-month follow-up remained off insulin with adequate glycemic control.
"These findings are very encouraging, suggesting that ReCET is a safe and feasible procedure that, when combined with semaglutide, can effectively eliminate the need for insulin therapy," Busch said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.